Potential new treatments for Parkinson’s disease, developed by researchers at Rush University Medical Center, show that they have been successful in slowing the progression of the disease in mice.
In a study published in Nature CommunicationsRush researchers found that two different peptides (chains of amino acids) help slow the spread of α-synuclein, a protein that occurs in abnormal protein deposits called Lewy bodies in the brain. bottom.Lewy body dementias is characteristic of Parkinson’s disease diseaseThe most common movement disorder affecting approximately 1.2 million people in the United States and Canada.
“Currently, there is no cure to slow the progression of Parkinson’s disease. It only cures the symptoms,” said Dr. Kalipada Pahan, a professor of neurology and research career scientist at Rush University Medical Center. Jesse Brown VA Medical Center, which led the study.
Lewy bodies are also associated with the development of rare neuropathy called Lewy body dementias and multiple system atrophy (MSA). “Current, Effective treatment In the case of Lewy body dementias and multiple system atrophy, understanding how these disorders work is effective in controlling the pathology of α-synuclein, protecting the brain, and stopping the progression of Lewy. It is important for developing various medicines. body sick. “
The lab-developed peptides tested in this study are known as the TLR2 interaction domain (TIDM) and NEMO binding domain (NBD) of Myd88. The nasal drug was found to slow brain inflammation and stop the spread of α-synuclein in Parkinson’s disease mice. Treatment also improved gait, balance, and other motor function in mice.
“If we can reproduce these results in patients, it will be a remarkable advance in the treatment of catastrophic neuropathy,” says Pahan.
This study was supported by funding from the National Institutes of Health. Other authors of this article are Debashis Dutta, Ph.D. is. Dr. Malavé de Jana; Moumita Majumder, Ph.D. Susanta Mondal, Ph.D. ; And Avik Roy, Ph.D. , All from Rush University Medical Center.
Selective targeting of the Debashis Dutta et al, TLR2 / MyD88 / NF-κB pathway reduces the diffusion of α-synuclein in vitro and in vivo. Nature Communications (2021). DOI: 10.1038 / s41467-021-25767-1
Rush University Medical Center
Quote: Nasal medicine is a lab study obtained on September 21, 2021 from https: //medicalxpress.com/news/2021-09-nasal-drugs-parkinson-disease-lab.html (September 21, 2021) Shows the potential to slow the progression of Parkinson’s disease
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
Nasal drugs show promise for slowing Parkinson’s disease progression in lab study Source link Nasal drugs show promise for slowing Parkinson’s disease progression in lab study